TY - GEN AU - Aranda, Enrique AU - Viéitez, Jose Maria AU - Gómez-España, Auxiliadora AU - Gil Calle, Silvia AU - Salud-Salvia, Antonieta AU - Graña Suárez, Begoña AU - Garcia-Alfonso, Pilar AU - Rivera, Fernando AU - QUINTERO ALDANA, GUILLERMO AU - Reina-Zoilo, Juan José AU - González-Flores, Encarnación AU - Salgado Fernández, Mercedes AU - Guillén-Ponce, Carmen AU - Garcia-Carbonero, Rocio AU - Safont, María José AU - La Casta Munoa, Adelaida AU - García-Paredes, Beatriz AU - López López, Rafael AU - Sastre, Javier AU - Díaz-Rubio, Eduardo AU - Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) PY - 2020 SN - 2059-7029 UR - http://hdl.handle.net/20.500.11940/16221 AB - PURPOSE: 5-Fluorouracil/leucovorin, oxaliplatin, irinotecan (FOLFOXIRI) plus bevacizumab is more effective than doublets plus bevacizumab as first-line therapy for metastatic colorectal cancer, but is not widely used because of concerns about toxicity... KW - Organoplatinum Compounds KW - Humans KW - Camptothecin KW - Fluorouracil KW - Leucovorin KW - Antineoplastic Combined Chemotherapy Protocols TI - FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ?3 circulating tumour cells: the randomised phase III VISNÚ-1 trial DO - 10.1136/esmoopen-2020-000944 KW - CHUAC KW - CHUS KW - CHUO KW - IDIS VL - 5 ER -